TABLE 3.
Author, year | No. of | Cut-off | Comments | Risk assessment |
---|---|---|---|---|
cases | values | determined by | ||
Shroff et al. 52 | 92 | 0, 1–3, or > 3 | Disease-free and overall survival | |
Sakata et al.53 | 71 | 0, 1–3, or ≥4 | The number of positive LNs better predicts the outcome than the LN ratio |
|
Lee et al.54 | 52 | ≥3 | In univariate analysis, the number of positive LNs, and LN ratio and LN location are significantly correlated with survival |
Recurrence and survival |
In multivariate analysis, the factor of ≥3 metastatic LNs is the only independent prognostic factor |
||||
Choi et al.55 | 78 | 0–1 or ≥ 2 | LN number and presence of metastatic LNs do not affect overall survival |
Recurrence and overall survival |
≥2 metastatic LNs significantly affects disease-free survival | ||||
Sommerville et al.56 | 39 | 0, 1–3, or > 3 | >3 vs. 0 metastatic LN hazard ratio is significant | Overall survival |
Sierzega et al.57 | 111 | ≥4 | In univariate analysis, the presence of metastatic LNs, and their number and ratio are significantly correlated with survival |
Overall survival |
Sakata et al.58 | 62 | 0, 1–3, or ≥4 | The number, not the location, of metastatic LNs independently affects long-term survival |
Overall survival |
LNs lymph nodes